Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
暂无分享,去创建一个
Christian Gerdes | G. Himmler | M. Schuster | G. Waxenecker | H. Loibner | P. Umaña | Pablo Umana | C. Gerdes | C. Ferrara | P. Brünker | S. Wiederkum | G. Mudde | C. Schwager | Manfred Schuster | Claudia Ferrara | Peter Brünker | Günter Waxenecker | Susanne Wiederkum | Cornelia Schwager | Hans Loibner | Gottfried Himmler | Geert C Mudde
[1] L. Buck,et al. Enhancement of therapeutic protein in vivo activities through glycoengineering , 2003, Nature Biotechnology.
[2] PETER W. RUNSTADLER,et al. The Importance of Cell Physiology to the Performance of Animal Cell Bioreactors , 1992, Annals of the New York Academy of Sciences.
[3] R. Graziano,et al. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies , 1997 .
[4] J. Murray,et al. Monoclonal antibody therapy for solid tumors. , 2000, Cancer treatment reviews.
[5] B. Shopes,et al. A genetically engineered human IgG mutant with enhanced cytolytic activity. , 1992, Journal of immunology.
[6] V. Sexl,et al. Antibodies Directed against Lewis-Y Antigen Inhibit Signaling of Lewis-Y Modified ErbB Receptors , 2004, Cancer Research.
[7] Kazuya Yamano,et al. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. , 2004, Biotechnology and bioengineering.
[8] D. King,et al. High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.
[9] S. Hakomori,et al. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. , 1992, The New England journal of medicine.
[10] B. Yin,et al. Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer , 1996, International journal of cancer.
[11] Margit Jeschke,et al. Determination of the Origin of Charge Heterogeneity in a Murine Monoclonal Antibody , 2000, Pharmaceutical Research.
[12] S. Hakomori,et al. Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. , 1986, Cancer research.
[13] R. Graziano,et al. FcγR in Cytotoxicity Exerted by Mononuclear Cells (Part 1 of 2) , 1989 .
[14] H. Scherthan,et al. Gene Transfer and Amplification in CHO Cells , 1996, Annals of the New York Academy of Sciences.
[15] Shigeru Iida,et al. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.
[16] H. Katinger,et al. Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. , 2000, Biotechnology and bioengineering.
[17] G. Trempe. Human breast cancer in culture. , 1976, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[18] R. Ueda,et al. Analysis of the fine specificities of 11 mouse monoclonal antibodies reactive with type 2 blood group determinants. , 1990, Molecular immunology.
[19] M. Vásquez,et al. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys. , 1993, Cancer research.
[20] R. Jefferis,et al. IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation , 1998, Immunological reviews.
[21] J. Murray,et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Cordon-Cardo,et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens , 1997, International journal of cancer.
[23] T. Logtenberg,et al. High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6 , 2003, Biotechnology progress.
[24] J. Whang‐Peng,et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. , 1983, Cancer research.
[25] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.
[26] E. Gelfand. Antibody-directed therapy: past, present, and future. , 2001, The Journal of allergy and clinical immunology.
[27] F. Hesse,et al. Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. , 2000, Trends in biotechnology.
[28] W. Noé,et al. Appropriate mammalian expression systems for biopharmaceuticals. , 1998, Arzneimittel-Forschung.
[29] James E. Bailey,et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.
[30] C. Milstein,et al. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. , 1992, Biotechnology.
[31] K. Hellström,et al. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] J. Baars,et al. Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.
[33] R. Marcus,et al. Monoclonal antibody therapy for lymphoma. , 2003, Blood reviews.
[34] H. Schachter. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. , 1986, Advances in experimental medicine and biology.
[35] K. Sakakibara,et al. Establishment of cultured cell lines derived from a human gastric carcinoma. , 1978, The Japanese journal of experimental medicine.
[36] K. Shitara,et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.
[37] Kouhei Tsumoto,et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. , 2004, Journal of molecular biology.
[38] L. Presta,et al. Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.
[39] R. Graziano,et al. FcγR in Cytotoxicity Exerted by Mononuclear Cells (Part 2 of 2) , 1989 .
[40] D. Macdonald,et al. Expression of selectin ligands by cutaneous squamous cell carcinoma. , 1993, The American journal of pathology.
[41] M. Tallman. Monoclonal antibody therapies in leukemias. , 2002, Seminars in hematology.
[42] A. Dorner,et al. High level synthesis of immunoglobulins in Chinese hamster ovary cells. , 1990, Journal of immunology.
[43] K. Shitara,et al. Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.
[44] C. Cordon-Cardo,et al. Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. , 1986, Cancer research.
[45] C. Ballaré,et al. Differential lytic and agglutinating activity of the anti-Lewisx monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies , 1999, Cancer Immunology, Immunotherapy.
[46] R. Graziano,et al. Cytotoxicity mediated by human Fc receptors for IgG. , 1989, Immunology today.
[47] K. Hellström,et al. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. , 1990, Cancer research.
[48] R. W. Baldwin,et al. Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting , 2004, Cancer and Metastasis Reviews.
[49] K. Shitara,et al. Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism , 2004, Clinical Cancer Research.